Contact Us | Print Page | Sign In | Register
News & Press: CMSC Industry News for MS (INforMS)

CMSC INforMS: Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

Tuesday, March 26, 2019  
Posted by: Elizabeth Porco
Share |

Brief Summary:

Primary Objective: To determine the efficacy of SAR442168 in reducing the number of new brain lesions reported in Magnetic Resonance Imaging (MRI)

Secondary Objectives:

  • To evaluate the efficacy of SAR442168 on clinical symptoms and imaging measures
  • To evaluate the safety and tolerability of SAR442168

Detailed Description: The total study duration is 24 weeks which includes a screening period of 4 weeks, a treatment period of 16 weeks and a follow-up period of up to 4 weeks. Participants completing the Week 16 visit will be proposed to enroll in a long-term safety (LTS) follow-up study to assess safety and tolerability of SAR442168.

Study Type: Interventional(Clinical Trial)
Estimated Enrollment: 120 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis
ActualStudy Start Date: February 21, 2019
EstimatedPrimary Completion Date: December 2019
EstimatedStudy Completion Date: December 2019

Patients who are diagnosed with Relapsing Multiple Sclerosis may qualify for a new study titled “Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis”. More information is available in the study pamphlet and on https://clinicaltrials.gov/ct2/show/NCT03889639?term=dri15928&rank=1.


The Consortium of Multiple Sclerosis Centers

3 University Plaza Drive, Suite 116 Hackensack, NJ 07601

Tel: 201.487.1050 | Fax: 862.772.7275

info@mscare.org